Home > Publications Database > Chronic adaptive deep brain stimulation for Parkinson's disease: clinical outcomes and programming strategies. > print

001     280917
005     20250921001953.0
024 7 _ |a 10.1038/s41531-025-01124-7
|2 doi
024 7 _ |a pmid:40883328
|2 pmid
024 7 _ |a pmc:PMC12397205
|2 pmc
024 7 _ |a altmetric:180736912
|2 altmetric
037 _ _ |a DZNE-2025-01000
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Busch, Johannes L
|b 0
245 _ _ |a Chronic adaptive deep brain stimulation for Parkinson's disease: clinical outcomes and programming strategies.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758101471_31854
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Adaptive deep brain stimulation (DBS) dynamically adjusts stimulation amplitude based on neurophysiological feedback and may alleviate residual motor fluctuations in patients with Parkinson's disease. However, potential clinical benefits and programming strategies remain poorly understood. We programmed eight patients with Parkinson's disease on commercially available Dual Threshold adaptive DBS based on subthalamic beta power. Symptom severity was evaluated at home using ecological momentary assessments during two weeks of both continuous and adaptive DBS. Patients were not blinded to the stimulation mode. On the group level, overall well-being significantly improved with adaptive DBS (p = 0.007), and there was a non-significant trend toward enhanced general movement (p = 0.058). Within-subject analysis showed a significant improvement in overall well-being and general movement in three of eight patients. Six of eight patients chose to remain on adaptive DBS. Programming challenges included biomarker selection, threshold definition, and artifact-related maladaptation, for which targeted strategies are reported. Our findings support adaptive DBS as a potential option for selected Parkinson's disease patients with persistent motor symptoms on continuous DBS. We propose a three-step programming approach to guide clinical implementation of adaptive DBS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Kaplan, Jonathan
|b 1
700 1 _ |a Behnke, Jennifer K
|b 2
700 1 _ |a Witzig, Victoria S
|b 3
700 1 _ |a Drescher, Luisa
|b 4
700 1 _ |a Habets, Jeroen G V
|b 5
700 1 _ |a Kühn, Andrea A
|0 P:(DE-2719)2811089
|b 6
|e Last author
|u dzne
773 _ _ |a 10.1038/s41531-025-01124-7
|g Vol. 11, no. 1, p. 264
|0 PERI:(DE-600)2819218-7
|n 1
|p 264
|t npj Parkinson's Disease
|v 11
|y 2025
|x 2373-8057
856 4 _ |u https://pub.dzne.de/record/280917/files/DZNE-2025-01000%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280917/files/DZNE-2025-01000.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280917/files/DZNE-2025-01000.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280917
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811089
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)5000008
|k AG Kühn
|l Movement Disorders (Parkinson's disease, Dystonia)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000008
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21